Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New strategy aims to boost addiction treatment and curb HIV in central asia

NCT ID NCT05579470

Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a program to expand medication-assisted treatment for opioid addiction in Kazakhstan, Kyrgyzstan, and Tajikistan. Researchers will train local health officials and track how many people start and stay on treatment. The goal is to reduce HIV spread among people who inject drugs and their partners.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NIATx (a behavioral intervention to improve addiction treatment services)
What this could lead to
If successful, this could help more people with opioid addiction get effective treatment, reducing HIV transmission and improving health in Central Asia.
What could go wrong
This is an implementation study, not a test of a new drug. Success depends on local adoption and may not apply to other regions. Results are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 900 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: i. Aim 1: The inclusion criteria for Aim 1 Consists of: 1. Quantitative surveys for PWID 1. 18 years or older 2. Meeting DSM-V criteria for opioid dependence 3. Be either treatment naïve and seeking OAT or be on OAT for \< 90 days 2. Organizational Assessments for OAT Delivery Staff 1. 18 years or older 2. Currently working as an OAT delivery professional at an OAT delivery site 3. Focus Groups (PWID on OAT) 1. 18 years or older 2. Meeting DSM-V criteria for opioid dependence 3. Be either treatment naïve and seeking OAT or be on OAT for \< 90 days 4. Focus Groups (PWID not on OAT) 1. 18 years or older 2. Meeting Diagnostic and Statistical Manual of Mental Disorders(DSM)-V criteria for opioid dependence 3. Be OAT naïve (defined as never having been on OAT or having not received treatment for \> 1 year) 5. Focus Groups (OAT delivery staff) 1. 18 years or older 2. Currently working as an OAT delivery professional at an OAT delivery site ii. Aim 2: The inclusion criteria for Aim 2 consists of: 1. 18 years or older 2. Currently assigned as a Chief Narcologist for an Oblast iii. Aim 3: The inclusion criteria for Aim 3 consists of: 1. 18 years or older 2. Authorized as a professional to work at an OAT delivery site Exclusion Criteria: * Not willing to provide consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid-use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid-use disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Columbia University Global Health Research Center of Central Asia

    RECRUITING

    Almaty, Kazakhstan

  • Den Sooluk Nuru

    RECRUITING

    Bishkek, Kyrgyzstan

  • Institute for International Health and Education

    RECRUITING

    Dushanbe, Tajikistan

  • Yale University

    ACTIVE_NOT_RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.